Effect of angiotensin converting enzyme gene studies in nonalcoholic fatty liver disease subjects

Maram Al-Otaiby *

Molecular Genetic Pathology Unit, Department of Pathology, King Saud University, Riyadh, Saudi Arabia

ARTICLE INFO

Article history:
Received 9 March 2020
Received in revised form 12 June 2020
Accepted 30 July 2020

Keywords:
ACE
NAFLD
ID polymorphism
NASH
Non-NAFLD
Saudi population

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and type 2 diabetes. ACE gene is the key to involve with transforming Angiotensin-I to the potent vasoconstrictor of angiotensin-II, well-known for the association with all the above-mentioned diseases. Limited studies have been documented with NAFLD and ACE gene I/D polymorphism in the global studies, and there are no studies that have been documented in the Saudi population. The aim of the current study was to investigate the genetic association between angiotensin converting enzyme (ACE) gene, insertion (I)-deletion (D) polymorphisms in NAFLD in the Saudi population. NAFLD is a clinic pathological syndrome produced due to the environment, genetic, and metabolic stress-correlated factors, which are demonstrated clinically as fat accumulation in hepatocytes. This is a hospital-based case-control study implemented in 95 NAFLD cases and 78 non-NAFLD subjects. Genomic DNA was extracted in all the subjects to perform the PCR with ACE gene I/D polymorphism, and the current study results revealed the negative association between the NAFLD cases and controls in the Saudi population (DD vs II; OR = 0.19; 95%CI (0.05-0.43), p=0.04, DD+ID vs II; OR = 0.17; 95% CI (0.05-0.70), p=0.06 and D vs I; OR = 0.34; 95%CI (0.21-0.57), p=0.003. In conclusion, this study confirms NAFLD has no genetic role in the Saudi population with ACE gene I/D polymorphism analysis.

© 2020 The Authors. Published by IASE. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Non-communicable diseases (NCD) accounts finished 70% of overall deaths as per the global burden of disease study (Cai et al., 2020). Nonalcoholic fatty liver disease (NAFLD) is one of the NCD and is documented as the most common liver disease throughout the world (Eslam et al., 2018). NAFLD is categorized as through excessive hepatic lipid accumulation connected with metabolic abnormalities in the absence of excessive alcohol consumption (Llovet et al., 2012). NAFLD burden is ripening swiftly with the ongoing epidemics of obesity, diabetes, and metabolic syndrome (MetS). However, NAFLD was not known as an autonomous disease distinctly from obesity and diabetes since the long era (Chalasani et al., 2018). The disease NAFLD spectrum spreads from modest hepatic steatosis to the concomitant presence of inflammation, and ballooning is defined as non-alcoholic steatohepatitis, also known as NASH (Chen et al., 2020). The prevalence of NAFLD is assessed to be 25.2% globally, and the prevalence of NAFLD with type 2 diabetes (T2D) is known to be two-fold higher in the normal subjects, and 55% was known to be the complete prevalence of NAFLD among T2D. Worldwide, NASH prevalence was found to be 37.3% among T2D subjects (Younossi et al., 2019). Inclusion of NASH in NAFLD is a foremost cause of liver correlated morbidity and mortality, and NASH patients have a latent risk of emerging hepatocellular carcinoma (Kanda et al., 2020).

The genetic connection between the variables in the pathogenesis of NAFLD and NASH developments has been concerned (Kararr et al., 2019). Earlier studies showed that NAFLD could exist in the non-obese subjects of 10-20%, most frequently associated with central adiposity, recent weight gain, and genetic risk factors (Namjou et al., 2019). Limited information is documented for understanding in developing the progress of NAFLD, and it's known to be a complex metabolite state in which genetic and pathogenetic factors will take place along with the lifestyle (Liu et al., 2019a).
NAFLD is known to be associated with numerous neurotransmitters, hormones, and proinflammatory cytokines (Diehl et al., 2005; Chaldakov et al., 2003).

Genome-wide association studies (GWAS) have been established numerous genetic variants connected with remarkable risk factors for NAFLD disease (Liu et al., 2019b). NAFLD is also connected with genetics through family history, aggregational, functional, experimental, twin studies, as well as single nucleotide polymorphisms in the GWAS and candidate genes (Sookoian and Pirola, 2017). Renin angiotensin system is connected with multiple human diseases such as nephropathy, liver, kidney, osteoarthritis, lungs, obesity, hypertension (HTN), chronic inflammation, fibrosis, and oxidative stress (Marshall et al., 2000; Poornima et al., 2015). Angiotensin converting Enzyme-I (ACE) is the key to involve with transforming Angiotensin-I to the potent vasoconstrictor of angiotensin-II (Bastard et al., 2006).

The ACE gene insertion/deletion (I/D) polymorphism denotes the appearance or disappearance of 287bp of Alu sequence present at the intron 16 region (Khan et al., 2014). Limited studies have been documented in the NAFLD with ACE gene I/D polymorphism (Tekatas et al., 2016; Sydorchuk et al., 2018; Güçlü et al., 2010). There are no documented studies have been stated in the Saudi population between I/D polymorphism in the ACE gene. So, the current study aims to explore the genetic association between angiotensin converting enzyme insertion and deletion polymorphism in the Saudi subjects diagnosed with NAFLD.

2. Materials and methods

2.1. Study enrolment

In this case-control study, 95 NAFLD cases and 78 non-NAFLD (controls) were involved. This study was performed in the Molecular Genetic pathology unit at King Saud University. The NAFLD patients and controls have opted from the surgery department in the KKUH premises. The inclusion criteria of the NAFLD subjects were based on ultrasound results confirming enlarged fatty liver after reconfirmation through comprehensive virology screening, subjects with obesity, T2D, and insulin resistant subjects. A histopathological NAFLD Assessment Score (NAS) of patients’ liver biopsy in the final range of NAFLD. The histological findings of segment 4 liver biopsies fixed with formaldehyde and paraffin block sections stained with hematoxylin–eosin; Masson’s trichrome; Prussian blue were evaluated by a single pathologist. The exclusion criteria of the NAFLD subjects are viral hepatitis, alcoholic hepatitis, drug-induced hepatitis, α1-antitrypsin deficiency, and Wilson’s disease. The controls have opted for healthy subjects without any diseases. An ethical grant was received from IRB in the university premises, and informed consent was obtained from each patient involved in this study.

2.2. Molecular analysis

From each patient, 2ml of the peripheral blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes, and simultaneously liver tissue was also collected for extraction of genomic DNA for the molecular analysis. Using the EDTA blood, genomic DNA will be extracted using the kit-based method, and DNA will be quantified using NanoDrop, spectrophotometer to visualize the genomic DNA (Al-Mutawa, 2019). Genotyping for 287bp Alu sequence was carried out with polymerase chain reaction (PCR), and primers were adapted from Khan et al. (2014). PCR profile comprises denaturation (95°C-30s), annealing (60°C-30s), extension (72°C-45s) with the involvement of initial denaturation, and final extension of 35 cycles. The PCR products were detected through 3% gel electrophoresis with ethidium bromide stained gel. Insertion is defined as 490bp, deletion as 190bp, and both the insertion and deletion as 490/190bp (Fig. 1).

![Fig. 1: Agarose gel representation of ACE gene I/D polymorphism](image)

2.3. Statistical analysis

Hardy Weinberg equilibrium (HWE) test was implemented to determine by the genotypes in NAFLD cases and the controls. The clinical analysis was performed with SPSS software (version 23.0). Continuous variables were measured with the mean±standard deviations and categorical variables with the percentages and their frequencies. Genotype and allele frequencies were carried out with Openepi software (version 3.01) (Khan et al., 2019). The P-values of <0.05 is considered as significant association.

3. Results

Genotype distribution between allele and genotypes for ACE I/D gene polymorphism is
regulated using the HWE. In this study, 95 NAFLD cases and 78 controls were involved in this study. The baseline characteristics of NAFLD cases and controls were shown in Table 1.

Table 1: Anthropometric features of NAFLD and non-NAFLD subjects

| S. No | NAFLD (n=95) | Non-NAFLD (n=78) | pValue |
|-------|-------------|-----------------|--------|
| Age (Years) | 43.59±11.79 | 34.91±11.05 | 0.001 |
| Gender (M:F) | 30:64 | 15:63 | 0.55 |
| Weight (kg) | 83.9±15.37 | 78.1±15.79 | 0.01 |
| Height (cm) | 159.63±0.09 | 159.93±0.09 | 0.95 |
| BMI (kg/m²) | 32.9±5.93 | 30.5±5.79 | 0.008 |

The mean age of the NAFLD cases was 43.59±11.79, whereas in the controls, it was 34.91±11.05, and age was found to be a significant association (p=0.001). Gender was found to be almost similar and not associated (p=0.55). Weight (p=0.01) and height (p=0.95) showed the association with BMI (p=0.008) in the NAFLD cases when compared with the controls. Allele and genotype frequencies showed in Table 2.

The genotype frequencies in the NAFLD cases were 16.8% of II, 40% of ID, and 43.2% for DD, and allele frequencies were found to be 63.2% in the D allele and 36.8% in I allele. The control groups showed 3.8% of II, 39.8% ID, and 56.4% of DD genotype association. 76.2% and 23.8% was the allele frequencies for D and I. None of the genotype model was found to be associated significantly (DD vs II; OR:0.17; 95% CI (0.04-0.64), p=0.04, DD+ID vs II: OR:0.19; 95% CI (0.05-0.70), p=0.006 and D vs I; OR:0.34; 95% CI (0.21-0.57), p=0.003.

Table 2: Genotype and allele frequency distributions in NAFLD and control subjects

| ACE (ID) | NAFLD (n=95) | Non-NAFLD (n=78) | OR     | 95%CI   | P-Value |
|----------|-------------|-----------------|--------|---------|---------|
| II       | 16 (16.8%)  | 03 (3.8%)       | -      | Reference | -       |
| ID       | 41 (43.2%)  | 44 (56.4%)      | 0.22   | 0.06-0.86 | 0.02    |
| DD       | 38 (40%)    | 75 (96.2%)      | 0.17   | 0.04-0.64 | 0.04    |
| ID vs DD | 79 (83.2%)  | 75 (96.2%)      | 0.19   | 0.05-0.70 | 0.006   |
| D vs II  | 41 (43.2%)  | 44 (56.4%)      | 0.55   | 0.30-1.01 | 0.05    |
| I        | 70 (36.8%)  | 37 (23.8%)      | -      | Reference | -       |
| D        | 120 (63.2%) | 119 (76.2%)     | 0.34   | 0.21-0.57 | 0.003   |

4. Discussion

The aim of the present study was to investigate the genetic association with ACE gene polymorphism studies in NAFLD patients in the Saudi population. The current study will be documented as the initial study in the Saudi population. The HWE was shown to deviate between the NAFLD cases and controls. The current study results showed the non-significant association when compared between NAFLD cases and controls within the Saudi population. Allele and genotype frequencies were found to be a significant association. Genotype frequencies between deletion (56.4% in controls and 43.2% in cases) and heterozygous (40% in NAFLD cases and 39.8% in controls) were found high in non-NAFLD when compared with cases.

ACE (EC 3.4. 15.1) is a central component of RAS that controls HTN through regulating the volume of fluids in the body, which converts Angiotensin I to Angiotensin II by vasoconstrictor and also inactivates the bradykinin (Shen et al., 2012). ACE gene is a zinc metallopeptidase that appears on chromosome17q23. It is one of the utmost genetic variables responsible for the variability of ACE serum activity (Khan et al., 2014; Poornima et al., 2015). II, ID, and DD are the three types of genotypes that exist in the human population. Till now, the complete pathogenesis is not confirmed (Zhang et al., 2019). There are limited studies have been recorded with NAFLD in the global population and showed both significant and non-significant association (Güclü et al., 2010; Tekatas et al., 2016; Sydorchuk et al., 2018). Our study is also in agreement with the previous studies, which showed a negative association (P>0.05).

Meta-analysis studies are defined as the statistical analysis of a large collection of analysis results from specific studies for the purpose of integrating the findings. The concept of performing meta-analysis studies is to confirm the statistical procedure of the combined data of the global studies and also based on single study results, the utility of an intervention of a hypothesis cannot be done (Haidich, 2010), and it has been proven by an enormous number of meta-analysis studies. ACE gene polymorphism has been implemented the meta-analysis studies in almost all the human diseases and showed both the effects of association (Ahmad et al., 2019; Aslbahar et al., 2018; Han et al., 2017; Luo et al., 2016; Mengesha et al., 2019; Xu et al., 2018; Yuan et al., 2017; Zheng and Huang, 2020). However, there are no meta-analysis studies have been documented due to the limited number of global studies have been documented.

NAFLD is known to be chronic liver disease and affects up to 25% globally. NASH cirrhosis is connected with NAFLD through the growth with a 170% growth in cirrhosis. NASH cirrhosis is known to be the leading indication for liver transplantation. The major risk factors for NAFLD are associated with Insulin resistance, obesity, and T2D (Danford et al., 2018). The sub-studies in the Danford et al. (2018) studies have documented the heritability of NAFLD disease within the affected families. Family aggregational studies confirmed NAFLD affected overweight children have major chances to inherit the disease when compared with overweight children without the disease. In our study, the BMI for opted NAFLD patients (n=95) were found to be as; 8 of them were normal weight, overweight was documented to be 28 patients, obesity 1 and obesity
2&3 were enrolled as 32 and 27 NAFLD patients. However, the BMI data for the enrolled patients were not recorded.

A mutation in rs738409C>G in the PNPLA3 gene is confirmed using the genome-wide association studies. The rs738409C>G variant is known to be I148M mutation is the initial allele associated with intrahepatic fat content, which appears to be a major genetic determinant of hepatic steatosis in the growth of NAFLD (Romeo et al., 2008). The rs58542926C>T, rs780094C>T, and rs641738C>T variants in the TM6SF2, GCKR, and MBOAT7 genes are connected with hepatic steatosis and NAFLD (Danford et al., 2018). In this study, single ACE gene polymorphism was studied and implemented, and the current study data showed the negative association. In the Saudi population, ID polymorphism studies in the ACE gene has been implemented with different diseases and showed positive and negative associations (Alharbi et al., 2013a; 2013b; Al-Mutawa, 2018; Fawwaz et al., 2017; Sabir et al., 2019).

The strength of the current study was to involve Saudi subjects, and this is the first molecular-based study in the Saudi population. One of the limitations of this study is the low sample size, the single ID polymorphism, and missed out on the serum analysis. In conclusion, the present study in the Saudi population in NAFLD subjects showed a negative association with ACE I/D gene polymorphism studies. Future studies should be performed in the global population to implement the meta-analysis studies between ACE gene I/D polymorphism and NAFLD-NASH disease.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

Ahmad N, Jamal R, Shah SA, Gafor AH, and Murad NAA (2019). Renin–angiotensin–aldosterone system gene polymorphisms and type 2 diabetic nephropathy in Asian populations: An updated meta-analysis. Current Diabetes Reviews, 15(4): 263-276. https://doi.org/10.2174/1573399814666180709100411 PMid:29984662

Alharbi KK, Kashour TS, Al-Hussaini W, Al-Nbaheen MS, Mohamed S, Hasnato RM, and Khan IA (2013a). Association of angiotensin converting enzyme gene insertion/deletion polymorphism and familial hypercholesterolemia in the Saudi population. Lipids in Health and Disease, 12: 177. https://doi.org/10.1186/1476-511X-12-177 PMid:24289455 PMGid:PMC4220775

Alharbi KK, Khan IA, Abed AS, and Syed R (2013b). Insertion/Deletion polymorphisms do play any role in G6PD deficiency individuals in the Kingdom of the Saudi Arabia. Bioinformation, 9(1): 49-53. https://doi.org/10.26911/97320630009049 PMid:23390344 PMGid:PMC3563416

Al-Mutawa J (2018). Interaction with angiotensin-converting enzyme-encoding gene in female infertility: Insertion and deletion polymorphism studies. Saudi Journal of Biological Sciences, 25(8): 1617-1621. https://doi.org/10.1016/j.sjbs.2016.06.003 PMid:30591778 PMGid:PMC6303183

Al-Mutawa J (2019). Role of C677T polymorphism in the MTHFR gene in Saudi females affected with infertility. International Journal of Advanced and Applied Sciences, 6(6): 98-102. https://doi.org/10.21833/ijaas.2019.06.014

Ashabhar F, Neamat-zadeh H, Tabatabaeae RS, Karimi-Zarchi M, Jahveri A, Mazaheri M, and Nasiri R (2018). Association of angiotensin-converting enzyme insertion/deletion polymorphism with recurrent pregnancy loss: A meta-analysis of 26 case-control studies. Revista Brasileira de Ginecologia e Obstetricia/RBGO Gynecology and Obstetrics, 40(10): 631-641. https://doi.org/10.1055/s-0038-1672137 PMid:30352462

Bastard JP, Mauchi M, Laquthu C, Kim MJ, Caron M, Vidal H, and Feve B (2006). Recent advances in the relationship between obesity, inflammation, and insulin resistance. European Cytokine Network, 17(1): 4-12.

Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, and Li H (2020). Nonalcoholic fatty liver disease pandemic fuels the upsire in cardiovascular diseases. Circulation Research, 126(5): 679-704. https://doi.org/10.1161/CIRCRESAHA.119.316337 PMid:32105577

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinelia M, and Sanyal AJ (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1): 328-357. https://doi.org/10.1002/hep.29367 PMid:28714183

Chaldakov GN, Stankulov IS, Hristova M, and Ghenev P (2003). Adipobiology of disease: Adipokines and adipokine-targeted pharmacology. Current Pharmaceutical Design, 9(12): 1023-1031. https://doi.org/10.2174/1381612033455152 PMid:12678860

Chen Y, Cao D, Li C, Zhang P, Wang X, Li N, and Liu Z (2020). A homogram for discrimination of non-alcoholic fatty liver disease in patients with chronic hepatitis B. European Journal of Gastroenterology and Hepatology. https://doi.org/10.1097/MEG.0000000000001691 PMid:32118853

Danford CJ, Yao Z, and Jiang ZG (2018). Non-alcoholic fatty liver disease: A narrative review of genetics. Journal of Biomedical Research, 32(6): 389-400.

Diehl AM, Li ZP, Lin HZ, and Yang SQ (2005). Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut, 54(2): 303-306. https://doi.org/10.1136/gut.2003.024935 PMid:15647199 PMGid:PMC1774847

Eslam M, Valenti L, and Romeo S (2018). Genetics and epigenetics of NAFLD and NASH: Clinical impact. Journal of Hepatology, 67(1): 328-357. https://doi.org/10.1016/j.jhep.2017.09.003 PMid:29122391

Fawwaz S, Balbaba M, Fakhoury H, Borjajc J, and Fakhoury R (2017). Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease in Lebanese patients with diabetic nephropathy. Saudi Journal of Kidney Diseases and Transplantation, 28(2): 325-329. https://doi.org/10.4103/1319-2442.202789 PMid:28352015

Güçlü M, Yakar T, and Serin E (2010). Angiotensin converting enzyme gene (I/D) polymorphism and nonalcoholic fatty liver disease. European Journal of General Medicine, 7(2): 136-142. https://doi.org/10.29333/ejgm/82840
Haidich AB (2010). Meta-analysis in medical research. Hippokratia, 14(Suppl 1): 29-37.

Han C, Han X, Liu FC, and Huang JF (2017). Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta-analysis. Chronic Diseases and Translational Medicine, 4(4): 230-241. https://doi.org/10.1016/j.cdtm.2017.07.002 PMid:29354806 PMCi:PMCID:PMC5747497

Kanda T, Goto T, Hirotsu Y, Masuzaki R, Miyaraya M, and Omata M (2020). Molecular mechanisms: Connections between nonalcoholic fatty liver disease, steatohepatitis and hepatocellular carcinoma. International Journal of Molecular Sciences, 21(4): 1525. https://doi.org/10.3390/jms21041525 PMid:32102237 PMCi:PMCID:PMC7032310

Karrar A, Harirhan S, Fazel Y, Moosvi A, Houry M, Younoszai Z, and Monge F (2019). Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. Medicine, 98(32): e16704. https://doi.org/10.1016/j.md.2019.07.020 PMid:31393374 PMCi:PMCID:PMC6708789

Khan IA, Jahan P, Hasan Q, and Rao P (2014). Angiotensin-converting enzyme gene insertion/deletion polymorphism studies in Asian Indian pregnant women biochemically identifies gestational diabetes mellitus. Journal of the Renin-Angiotensin-Aldosterone System, 15(4): 566-571. https://doi.org/10.1177/1470203213502106 PMid:24189507

Khan IA, Jahan P, Hasan Q, and Rao P (2019). Genetic confirmation of T2DM meta-analysis variants studied in gestational diabetes mellitus in an Indian population. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 13(1): 688-694. https://doi.org/10.1016/j.dsx.2018.11.035 PMid:30641791

Liu M, Liu S, Shang M, Liu X, Wang Y, Li Q, and Nie F (2019a). Association between ADIPOQ G276T and C11377G polymorphisms and the risk of non-alcoholic fatty liver disease: An updated meta-analysis. Molecular Genetics and Genomic Medicine, 7(5): e624. https://doi.org/10.1002/mgg3.3624 PMid:30838812 PMCi:PMCID:PMC6503060

Liu Q, Liu SS, Zhao ZZ, Zhao BT, Du SX, Jin WW, and Xin YN (2019b). TRIB1 rs17321515 gene polymorphism in patients with nonalcoholic fatty liver disease and C-reactive protein levels. Journal of the Renin-Angiotensin-Aldosterone System, 20(3): 147032019870945. https://doi.org/10.1002/mgg3.624

Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, and Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, and Hobbs HH (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 40(12): 1461-1465. https://doi.org/10.1038/ng.257 PMid:18820647 PMCi:PMCID:PMC2597056

Mengesha HG, Petrucca P, Spence C, and Taallees TB (2019). Effects of angiotensin converting enzyme gene polymorphism on hypertension in Africa: A meta-analysis and systematic review. PloS One, 14(2): e0211054. https://doi.org/10.1371/journal.pone.0211054 PMid:30763326 PMCi:PMCID:PMC6375551

Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway JB, and Wei WQ (2019). GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE network. BMC Medicine, 17: 135. https://doi.org/10.1186/s12916-019-1364-z PMid:31311600 PMCi:PMCID:PMC6636057

Poornima S, Subramanyan K, Khan IA, and Hasan Q (2015). The insertion and deletion (I28205D) polymorphism of the angiotensin I converting enzyme gene is a risk factor for osteoarthritis in an Asian Indian population. Journal of the Renin-Angiotensin-Aldosterone System, 16(4): 1281-1287. https://doi.org/10.1177/1470320314547403 PMid:25178458

Romeo S, Koditina J, Xing C, Pertemisidis A, Cox D, Permacchio LA, and Hobbs HH (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 40(12): 1461-1465. https://doi.org/10.1038/ng.257 PMid:18820647 PMCi:PMCID:PMC2597056

Sabir JS, Omri AE, Ali Khan I, Banaganapalli B, Hajrah NH, Zreli H, and Altaf A (2019). ACE insertion/deletion genetic polymorphism, serum ACE levels and high dietary salt intake influence the risk of obesity development among the Saudi adult population. Journal of the Renin-Angiotensin-Aldosterone System, 20(3): 147032019870945. https://doi.org/10.1002/mgg3.624

PMCi:PMCID:PMC6732865

Shen XZ, Ong FS, Bernstein EA, Janjula T, Blackwell WLB, Shah KH, and Bernstein KE (2012). Nontraditional roles of angiotensin-converting enzyme. Hypertension, 59(4): 763-768. https://doi.org/10.1161/HYPERTENSIONAHA.111.188342 PMid:22353608 PMCi:PMCID:PMC3306543

Sookoian S and Pirloja CJ (2017). Genetic predisposition in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 23(1): 1-12. https://doi.org/10.3350/cmh.2016.0109 PMid:28268262 PMCi:PMCID:PMC5381829

Sydorchuk L, Yarynych Y, Knut R, Sydorchuk A, Matyukha L, Sydorchuk O, and Sydorchuk R (2018). Hepatocytes’ function and adipokines in patients with non-alcoholic fatty liver disease depending on the ace (rs4646994) and PPARgamma2 (rs1801282) genes’ polymorphisms. The Medical-Surgical Journal, 122(2): 358-364. https://doi.org/10.1186/s12916-019-1109-2 PMid:31470861 PMCi:PMCID:PMC6717352

Teaktas DD, Bahcecioglu IU, Isiproglu M, Sahin A, Ibhan N, Yalnz M, and Demirel U (2016). Role of Renin-Angiotensin-converting enzyme level and ACE gene polymorphism in patients with nonalcoholic fatty liver disease. Eurasian Journal of Hepato-Gastroenterology, 6(2): 137-142. https://doi.org/10.5005/jp-journals-10018-1186 PMid:29201746 PMCi:PMCID:PMC5578582

Xu G, Fan G, Sun Y, Yu L, Wu S, and Niu W (2018). Association of angiotensin-converting enzyme gene I/D polymorphism with chronic obstructive pulmonary disease: A meta-analysis. Journal of the Renin-Angiotensin-Aldosterone System, 19(2): 1470320319770546. https://doi.org/10.1177/1470320319770546 PMid:29716409 PMCi:PMCID:PMC5954319

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, and Nader F (2019). The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology, 71(4): 793-801. https://doi.org/10.1016/j.jhep.2019.06.021 PMid:31279902

Yuan Y, Meng L, Zhou Y, and Lu N (2017). Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: A systematic review and meta-analysis. Medicine, 96(48): e8639.
Zhang Y, Yang T, Zhou W, and Huang Y (2019). A meta-analysis on the association of genetic polymorphism of the angiotensin-converting enzyme and coronary artery disease in the Chinese population. Revista da Associação Médica Brasileira, 65(6): 923-929.
https://doi.org/10.1590/1806-9282.65.6.923
PMid:31340327

Zheng Y and Huang J (2020). Angiotensin-converting enzyme gene insertion/deletion polymorphism and high-altitude pulmonary edema: An updated meta-analysis. Journal of the Renin-Angiotensin-Aldosterone System, 21(1): 1470320319900039.
https://doi.org/10.1177/1470320319900039
PMid:32106754 PMCid:PMC7052470